U. Minnesota Drug Patents
Executive Summary
Sen. Boschwitz (R-Minn.) introduced legislation Feb. 7 to extend the patents of two cardiac drugs developed by the University of Minnesota -- the injectable anti-arrhythmic bretylium tosylate (American Critical Care's Bretylol) and the oral antihypertensive bethanidine sulfate (Robins' Tenathan). The bill (S 456) would provide five-year extensions for bretylium and bethanidine, whose patents expire in 1986 and 1987, respectively. Both drugs were approved in 1981. Boschwitz said industry or university funding of comparative studies is "impracticable" unless the patents are extended. He added that Senate Judiciary/Patents Subcmte. Chairman Mathias (R-Md.) has agreed to hold hearings on the bill
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.